INKT

MiNK Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in New York, dedicated to developing innovative allogeneic invariant natural killer T-cell therapies aimed at addressing cancer and immune-mediated diseases. With a focus on harnessing the unique properties of these immune cells, MiNK is positioning itself at the forefront of next-generation cell-based immunotherapies. The company is committed to pioneering novel treatment options that have the potential to significantly enhance patient outcomes and transform therapeutic strategies in the oncology and immunology landscapes.